Analysis of Promyelocytic Leukemia in Human Embryonic Carcinoma Stem Cells During Retinoic Acid-Induced Neural Differentiation

Khadijeh Karbalaie 1,2, Sadeq Vallian 1*, Liana Lachinani 3, Somayeh Tanhaei 4, Hossein Baharvand 5,6**, Mohammad Hossein Nasr-Esfahani 2**

1Division of Genetics, Department of Biology, Faculty of Science, University of Isfahan, Isfahan, Iran
2Department of Cellular Biotechnology, Cell Science Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran
3Department of Cell and Molecular Biology, Cell Science Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran
4Department of Molecular Genetics, Cell Science Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran
5Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
6Department of Developmental Biology, University of Science and Culture, Tehran, Iran

*Corresponding author: Sadeq Vallian, Division of Genetics, Department of Biology, Faculty of Science, University of Isfahan, Isfahan, Iran. Tel/Fax: +98-3137932456, E-mail: svallian@sci.ui.ac.ir
**Co-Corresponding authors: Mohammad Hossein Nasr-Esfahani, Department of Cellular Biotechnology, Cell Sciences Research Center, Royan Institute for Biotechnology, ACECR, Isfahan, Iran. Tel: +98-3195015680, Fax: +98-3195015687, E-mail: mh.nasr-esfahani@RoyanInstitute.org
Hossein Baharvand, Department of Stem Cells and Developmental Biology, Cell Sciences Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran. Tel: +98-2122306485, Fax: +98-2122310406, E-mail: Baharvand@RoyanInstitute.org

Received: August 19, 2015; Revised: December 10, 2015; Accepted: March 05, 2016

Background: Promyelocytic leukemia protein (PML) is a tumor suppressor protein that is involved in myeloid cell differentiation in response to retinoic acid (RA). In addition, RA acts as a natural morphogen in neural development.

Objectives: This study aimed to examine PML gene expression in different stages of in vitro neural differentiation of NT2 cells, and to investigate the possible role of PML in pluripotency and/or neural development.

Materials and Methods: RA was used as a neural inducer for in vitro neural differentiation of NT2 cells. During this process PML mRNA and protein levels were assessed by quantitative real time RT-PCR (QRT-PCR) and Immunoblotting, respectively. Furthermore bisulfite sequencing PCR (BSP) was used to assess PML promoter methylation in NT2 cells and NT2 derived neuronal precursor cells (NT2.NPCs).

Results: QRT-PCR results showed that, PML had maximum expression with significant differences in NT2 derived neuronal precursor cells relative to NT2 cells and NT2 derived neural cells (NT2.NCs). Numerous isoforms of PML with different intensities appeared in immunoblots of pluripotent NT2 cells, NT2.NPCs, and NT2.NCs. Furthermore, the methylation of the PML promoter in NT2.NCs was 2.6 percent lower than NT2 cell.

Conclusions: The observed differences in PML expression in different cellular stages possibly could be attributed to the fact that PML in each developmental state might be involved in different cell signaling machinery and different functions. The appearance of different PML isoforms with more intensity in neural progenitor cells; may suggest a possible role for this protein in neural development.

Keywords: Pluripotent stem cells; Promyelocytic Leukemia; Retinoic acid

1. Background

Human PML gene is located on chromosome 15 (15q) (NC_000015.10; 74287014…74340160). PML protein has several motifs, including an RBCC domain (two zinc finger domains, B boxes, and an α-helical coiled-coil motif), nuclear localization signal (NLS), and a serin/prolin rich domain (1). This protein was known as the one of the major components of the promyelocytic leukemia nuclear bodies (PML-NBs). Retinoic acid (RA) acts as a natural morphogen in neu-
ral development and as a key component of RA-dependent myeloid differentiation (2-4). Different pluripotent cell lines were differentiated to mature in vitro neural cells after RA treatment.

CpG islands (or CG islands) are at least 200 nucleotide regions with more than 50% GC and 65% CpG ratio (5, 6). These islands could be considered as indicative of vertebrate genome, which are present in almost 70% of vertebrate promoters (7). More than 50% of human genes have these islands at their promoters (8). It has been documented that housekeeping genes, developmental regulatory genes, and tissue specific genes have promoters that possess CpG islands which are called CpG promoters (9-12). A number of factors are known to contribute in the control of gene expression in CpG promoters. These factors include the binding of specific transcription factors such as specific protein one (SP1), the presence of active epigenetic marks and open chromatin structures accessible for transcription machinery (13, 14). Among the epigenetic markers, DNA methylation has an important role in the control of gene expression in CpG promoters. Conversion of cytosine to methyl-cytosine in CpG dinucleotides changes DNA sequence accessibility for active transcription factors, producing compact chromatin structures unsuitable for transcription. DNA methylation as a long term epigenetic mark occurs in CpG promoters of pluripotent and pluripotent associated genes in stem cells (15).

2. Objectives
With regard to the fact that stem cells are a suitable model for in vitro mammalian developmental studies, this study aims to investigate the possible role of PML in pluripotency and/or neural development after RA treatment. Furthermore, considering DNA methylation as a key factor in the normal development and differentiation process, the DNA methylation pattern of the PML promoter in pluripotent stem cells and EC-derived neural cells (NCs) will also be addressed.

3. Materials and Methods

3.1. Culture and Differentiation of Embryonic carcinoma Stem Cells (ECSCs)
The embryonic carcinoma stem cell line (ECSCs;NT2) was cultured in DMEM (Gibco, UK) supplemented with FCS (Gibco) and 2 mM L-glutamine. Cell passage was carried out by treatment with trypsin (Gibco), and cells were seeded in new dishes at a 1:5 ratio. Neural induction of these cells was accomplished in growth medium supplemented with different inducers and factors over a three-month period. Initially, 2×10⁴ cells/cm² were seeded in adherent tissue culture dishes in the presence of 10 μM RA for a month. The resultant compact neuro epithelial cells were dissociated by trypsin and seeded in a 3:7 ratio in new adherent culture dishes in the presence of 1 μM cytosine arabinosin (Sigma, USA) only for the first week of this period, 10 μM fluorodeoxyuridine (Sigma, USA) and 10 μM uridine for a month. For neural maturation, the apparent cell aggregates were mechanically dissociated by hitting to the side of the tissue culture dish. Dislodged aggregates were seeded in poly-D-lysine (Sigma)-coated dishes in the presence of 1 μM cytosine arabinosin (for the first week) and 10 μM fluorodeoxyuridine (16).

3.2. RNA Isolation and Quantitative Real-time PCR
Total RNA was extracted from three different stages of the neural differentiation process of NT2 cells by TRI reagent (Sigma, USA). Samples were treated with DNasel (Fermentas, Germany) to remove contaminating genomic DNA. cDNA synthesis was carried out using the Revert Aid First Strand cDNA Synthesis Kit and random hexamer primers (ThermoScientific). Real time PCR was performed with an Applied Biosystems (version 2.1) thermal cycler. Each PCR reaction was performed in triplicate using SYBR Green PCR Master Mix (Takara Bio. Inc., Japan), 2.5 pm of each primer and 25 ng cDNA in a final volume of 10 μL. Real time PCR data were normalized by GAPDH and relative gene expressions were analyzed by the comparative Ct method, 2—ΔΔCt (17). (Table 1) lists the sequence and the corresponding information for the Real-time PCR primers. The experiments were performed three times in three separate cultures in which cells were differentiated from stem cell stages to mature neural cells. Data from three independent repeats were assessed by one-way ANOVA analysis and presented as mean ± SEM.

3.3. Immunoblot Analysis
Protein extracts were prepared from three stages of neural differentiation process of NT2 cells by TRI reagent (Sigma). Solubilized protein fraction of each sample (30 μg) was subjected to SDS-PAGE electrophoresis and transferred to a poly vinylidene fluoride (PVDF) membrane. The membrane was soaked in 5% (w/v) skim milk as a blocking solution, rabbit anti-PML antibody (0.5 μg.mL⁻¹, Santa Cruz, USA) and mouse anti-ACTIN antibody (4 μg.mL⁻¹, Sigma) as first anti-
bodies followed by horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (Dako, Denmark) and HRP-conjugated goat anti-rabbit IgG (Santa Cruz) as secondary antibodies. HRP-conjugated IgGs bound to each protein band were visualized by an Amersham ECL advance Western blotting detection kit (GE Healthcare, Amersham Bioscience, UK).

3.4. DNA Extraction and Bisulfite Treatment

Genomic DNA of the NT2 cell line and NT2-derived neural cells (NT2.NCs) was extracted by the DN easy® Blood and Tissue Kit (Qiagen, Germany). Complete bisulfite conversion and DNA clean-up for methylation analysis was performed by the EpiTect® Bisulfite Kit (Qiagen, Germany).

3.5. Primer Design and Bisulfite Sequencing PCR

Meth Primer online software was chosen for primer design (www.urogene.org/MethPrimer). The primers used for amplification of PML were as: Forward, TTTTTGTAGTTTTGTTTTATTTTT and reverse, ATTA ACTAAATCCCTTAAACTATCC. The annealing temperature was 57ºC (Table 2). The PCR master mix was prepared according to Herman et al. with some modifications (18). Briefly, 300 ng of each forward and reverse primers was used for PCR reactions with 1 μL bisulfite modified DNA, 1× ammonium sulfate (AMS) buffer (Cina Clone, Iran), 6 mM MgCl2 (Cinna Gen, Iran), 1.25 mM dNTP (Cinna Gen, Iran), 0.6 U S-mar Taq (Cinna Gen) and 10 mM 2-mercaptoethanol (Sigma) in a 25 μL reaction volume. PCR reaction was carried out in an Eppendorf Master cycler gradient thermal cycler with the following program: 95ºC for 10 min, 35 cycles at 95ºC for 30 sec, 58ºC for 30 sec, and 72ºC for 1 min, followed by a final extension at 72ºC for 10 min. PCR products were subcloned into a pTZ57R/T cloning vector (InsTAclone™ PCR Cloning Kit, Fermentas, Germany) according to the manufacturer’s protocol. Ligated vectors were transferred into the DH5α strain of E. coli and grown colonies were selected by PCR analysis through both M13 and reverse sequencing primers. For each group, plasmids from 10 positive colonies were extracted by Qiaprep® Spin Miniprep Kit (Qiagen, Germany) and sequenced using standard M13 primers. The obtained sequences were analyzed with bisulfite sequencing DNA methylation analysis (BISMA) online software that defines the methylation pattern of the PML promoter (19). Using the software, parameters like lower threshold conversion rate and lower threshold sequence identity were chosen at 90%. The upper threshold of N-sites at the cytosine positions and the upper threshold insertions/deletions were chosen by 20%.

4. Results

4.1. Formation of Neural Precursor Cells (NPCs) and Neural Cells (NCs) from NT2 Cells

NT2 cells were differentiated in three stages over a three-month process (Figure 1A). Three or four angle NT2 cells (3 or 4 angle) with short and fine processes grew as adherent cell monolayer (Figure 1B). In culture medium that contained RA, NT2 cells propagated as blast slime cells such as neuroepithelial cells. As shown in (Figure 1C), these blast cells formed rosette-like structures in the background of NT2 cells. These heterogenic cultures were treated with trypsin and re-cultured in medium that contained mitotic inhibitors. After culture, the neuronal precursor cells (NT2.NPCs) appeared as shining clumps with large processes in the background of non-neuronal cells (Figure 1D). NT2 derived neural cells (NT2.NCs),

| Genes      | Forward Primer (5’-3’)       | Reverse Primer (5’-3’)       | AT*   | Accession No  |
|------------|-----------------------------|-------------------------------|-------|---------------|
| GAPDH      | CCACCTCCCTCACCTTTTGACG       | CCACCCACCTGTGTCGTTAG          | 56°C  | NM_002046.3   |
| POU5F1     | TTCTATTTTGGGAAAGTTCTCAGC    | ATTTGTTGCAGTTCTTCACCA         | 60°C  | NM_001173531.1|
| NANOG      | CGACTCACAAACAGGTGAAGAC      | TGTTGTTAGGAAAGAGTAAAGG        | 56°C  | NM_024865.2   |
| NESTIN     | TCCAGGAGACGGAAAATCAAG       | TTCTCTTGTCAGCGACAGT            | 55°C  | NM_006617.1   |
| PAX6       | CAGCTCGGTTGTGCTTTTGG       | AGTCGACTACCTGCGTTTTTA         | 57°C  | NM_001127612.1|
| TUJ1       | AAAGCCACAGCAGTTCATAACCC     | GGAGGGAGGAGGGCATATAAC         | 60°C  | NM_006086.2   |
| NCAM       | CTCGCCCCCTTGGTCTTTTGGAG    | TGCCAGGAGATGGCAAAAGT           | 57°C  | NM_181351.3   |
| PML        | ACCTTCGTGTTTTTGTGACTCTAAG  | GAACATCCTCCTCCGGCTTCA         | 62°C  | NM_033238.2   |
| PML-E2-E3  | CGCAAGACCAACACATC           | GAACATCCTCCTGGAGTAG           | 56°C  | NM_033238.2   |

*: AT is annealing temperature

Table 1. Primers that were used for gene expression analysis by QRT-PCR

Iran J Biotech. 2016;14(3):e1358
which were pure single neurons or clumps of mature
eurons (MN) with numerous neurites formed after
one month culture of NT2.NPCs in the presence of
mitotic inhibitors (Figure 1E).

4.2. Gene Expression Pattern of NT2 Cells Changes
Alongside Neural Differentiation

In NT2 cells, expressions of \textit{OCT4} and \textit{NANOG}
decreased in NT2.NPCs and NT2.NCs (Figure 2A).
Expressions of \textit{NESTIN} and \textit{PAX6}, two neural precurs-
or markers, were significant in NT2.NPCs. However,
there was no significant expression of these markers in
NT2 cells and in NT2.NCs (Figure 2B). Expressions of
\textit{TUJ1} and \textit{NCAM}, two neuronal markers, was not
detected in NT2 cells (Figure 2C). In contrast,
increased expressions of these markers were observed
in NT2.NPCs and NT2.NCs. This level of expression
was significantly higher compared to NT2 cells
(Figure 2C).

In parallel with these gene expression assessments,
a very slight level of \textit{PML} expression was noted in
NT2 cells (Figure 3A). Following RA treatment and
neural induction, higher levels of \textit{PML} and \textit{PML E2-E3}
expressions were detected in NT2.NPCs compared
to NT2 cells. However and at the end of the differenti-
ation process, \textit{PML} and \textit{PML E2-E3} expressions in
NT2. Ncs decreased with a level similar to NT2 cells
(Figure 3A). Immunoblotting was performed on the
extracts of NT2 cells, NT2.NPCs and NT2.NCs showed
the presence of different PML isoforms. On
the extracts of the NT2 cells, seven bands in the range
of 70-200 kDa were observed. In NT2.NPCs, the same
pattern with increased intensity was detected.
However, in NT2.NCs, there was no 170 kDa PML

![Figure 1](image1.png)

**Figure 1.** The identity of NT2 cells changed following retinoic
acid (RA) treatment. A: Schematic diagram of neural induction in
NT2 cells by sequential RA and mitotic inhibitor treatment. B:
NT2 cell line in pluripotent state grew as cell monolayer. C: In the
presence of RA, the cells form rosette-like structures contained
blast cells. D: NT2.NPCs formed in the presence of mitotic
inhibitors. E: Pure mature neurons (MN) appeared after three
months of NT2 neural induction.

![Figure 2](image2.png)

**Figure 2.** Gene expression of NT2 cells changed following
retinoic acid (RA) treatment. A: Relative expression level of
pluripotency genes decreased in neural cells. B: Relative expres-
sion level of neural precursor genes was higher in NT2.NPCs. C:
Neuronal genes had maximum expression in NT2.NCs. Means with
similar letters are significantly different (Tukey, LSD, p<0.05)
isoform. Two sharp bands within 130 kDa were observed and also the intensity of the other bands with lower molecular weights was attenuated (Figure 3B).

4.3. Bisulfite Sequencing PCR of the PML Promoter in NT2 and NT2.NPCs

The human PML promoter region from -809/+800 relative to the transcription start site (74286205-74287814) was imported as an input sequence in Meth Primer software (20). The promoter sequence was submitted in the main page of the software and primers were designed for BSP. Bioinformatic analysis showed one CpG island with 109 bp at 865-973 region in a TATA-less PML promoter (Figure 4A). This software, introduced a pair of primer suitable for BSP in upstream of the CpG island (Figure 3A and 4B). DNA samples extracted from NT2 and NT2.NPCs were subjected to BSP. PCR products were subcloned in a pTZ57R/T cloning vector and final positive clones used as the template for sequencing. Sequencing analysis by BISMA online software showed differences in NT2 cells and NT2.NPCs on the average methylation for each CpG site, the number of CpG sites, percent of DNA methylation, the average methylation over all sequences and the average methylation for each clone (Figure 4C and D). In NT2 derived clones, 4 clones out of 10 clones were methylated. These clones had only one methylated CpG in the third or fourth CpG dinucleotide of the predicted CpG island. Methylated CpGs were located in the 48 and 67 region of the CpG island and methylated 14.3 and 28.6 percent, respectively (Figure 4C). In NT2.NPCs derived clones only one CpG in the 198 region of the predicted CpG island, with 14.3 percent, was methylated (Figure 4D).

5. Discussion

The role of PML in granulocyte differentiation has been previously reported (21). However, to date, there is no report on the role of PML protein and methylation of its gene promoter in nervous system development and differentiation in human (22). Therefore, to understand the eventual role of this protein in neural development, NT2 pluripotent cell line were treated with RA as an accepted model for in vitro neural differentiation (3, 23). After RA treatment of pluripotent stem cells, NPCs with different patterns and morphologies were observed. Following adherent culture of NPCs, at the end of the neural differentiation process, NPCs were potentiated and changed to MNs with neuronal processes. It has been proved that in pluripotent stem cell lines parallel to neural differentiation process, expression of pluripotency genes such as OCT4 and NANOG decreased in stem cells and the expression of neural genes including MAP2 and TUJ1 increased in mature neuronal cells (24-28). This phenomenon, similar to other pluripotent stem cell lines, was observed in NT2 and NT2 derived neural cells and confirmed the proposed neural differentiation process. Assessment of PML expression in different stages of neural differentiation showed that PML had a minimum of expression in pluripotent NT2 cells and reached maximum expression after RA treatment in the neural precursor cells. In embryonic carcinoma cells, PML-NBs were shown to be involved in OCT4 expression and high level of PML expression was expected in NT2 cells. While higher PML expression in invasive and proliferative cells of liver carcinoma in contrast to lower PML expression in proliferative cells of lung cancer has been reported (29). Therefore, in the present study, since NT2 cells have been derived from
metastatic lung cancer, low \textit{PML} expression in NT2 cells might explain their metastatic nature of origin (lung) (30).

Furthermore, it is important to note that although NT2 cells are pluripotent cells, they have the ability to generate all three cell types of the central nervous system. Therefore, they are considered as neural progenitor cells (30). In view of the presence of \textit{PML} expression in proliferating neural progenitor cells of the developing mouse neocortex, it is belived that \textit{PML} probably involve in the proliferation of neural progenitor cells (31). In these cells, PML controls protein phosphatase-mediated dephosphorylation of retinoblastoma tumor suppressor protein (32).

In human cells, alternative splicing in the carboxy-terminal domains of \textit{PML} gene has generated varoiuse \textit{PML} isoforms. Regarding to this subject, assessment of the relative mRNA expression level of the first and longest isofrom carried out with one primer pair specific to the 8a-9 exon junction. Since there is no specific exon junction in other isoforms (there is a similar sequence), evaluation of all \textit{PML} isoforms specifically is impossible. Therefore, one primer pair complementary to the second and third exon junction, called \textit{PML} E2-E3, was used for assessment of the relative mRNA expression level of other \textit{PML} isoforms (33). The results indicated that the relative mRNA expression of the \textit{PML}I and all other \textit{PML} isoforms during neural differentiation in NT2 cells was similar in the three studied stages. This could be explained by the fact that since different isoforms have a different localization and probably different function in transfected fibroblast cells, the observed similar expression level could be possible and could not reject specific function for each isofrom. This may indicate that all \textit{PML} isoforms may cooperatively involve in different cellular activity.

Our immunoblot showed several bands representaive of different \textit{PML} isoforms in different stages of NT2 neural differentiation process. Interestingly, similar to QRT-PCR results (see above),the number and intensity of bands that express the presence of different \textit{PML} isoforms were higher in NT2.NPCs. It has been reported that post-translational modifications like sentrinization result in different \textit{PML} migrating isoforms (34, 35). Therefore these bands may relate to different \textit{PML} isoforms and or different forms of one isofroms of \textit{PML}. There is no report on the expression pattern of \textit{PML} isoforms in stem cells, nor in NCs derived from \textit{in vivo} or \textit{in vitro} embryos or cultures. In one report from Hsu and Everett only the increment of \textit{PML} and its presumed SUMO-1 modified form after RA treatment has been reported in neuron-like cells obtained from NT2 cells (36). It has been shown that PML in neocortex progenitor cells controls neural differentiation; and in cortex neurons by GluIA inhibition regulates synaptic strength (37). Therefore, the presence of several protein bands in both pluripotent cells and NCs may suggest that this protein, in addition to its possible role in pluripotency and proliferation, regulates synapse plasticity that has previously been reported in cortex neurons. Obviously, in view of diff-

Figure 4. Analysis of \textit{PML} promoter by Methprimer and BISMA online software programs. A: In a shematic representation of Methprimer software, the position of the CpG island with 109 base pair and the position of suitable BSP specific primer pair in upstream region of the CpG island is shown. B: Characteristics included the BSP specific primer sequences, melting temperatures and product length with the number of CpG nucleotides has been shown for the proposed PCR product. C: Results of BISMA online software analysis of PML promoter in NT2 cells showed one methylated CpG in three clones. D: Results of BISMA online software in NT2.NPCs showed one methylated CpG in only one clone
ferent post-translational modifications of the PML protein in different situations (38), further studies are required to fully decipher the nature of the PML protein bands and determine which is active in pluripotency and/or neural development.

Despite the presence of extensive reports on the different aspects of PML function, the importance of the methylation pattern of the PML promoter is unclear. Therefore, in the next step, the methylation pattern of the PML gene promoter was investigated in NT2 and mature neuronal cells. The process of neural differentiation in NT2 cells usually lasts three months and results in pure neuron cells. However, due to the differentiation in NT2 cells and NT2-NPCs, the PML promoter is differently methylated. The methylation pattern of the PML promoter differed in NT2 cells and NT2-NPCs, but in both cell types the PML promoter showed a low degree of methylation (3.9 percent in NT2 cells and 1.3 percent in NT2.NCs). Since NT2-NPCs and NT2-NCs were from a neural lineage, therefore, it was expected that these two cell types would have similar methylation patterns. The observed differential methylation pattern could be discussed in relation to the expression pattern of PML in these cells.

As mentioned above, quantitative RT-PCR (QRT-PCR) results showed that relative PML expression in NT2.NPCs was 30-fold more than NT2 cells. However according to our data, it is believed that the DNA methylation pattern could not solely describe the observed difference. It is possible that other factors may have contributed in this phenomenon. Further studies are required to determine if the difference in PML expression during neural differentiation of NT2 cells is related to differential CpG methylation or whether other factors regulate PML expression.

Acknowledgements

This study was funded by a grant provided from Royan Institute.

References

1. Freemont PS, Hanson IM, Trowsdale J. A novel gysteine-rich sequence motif. Cell 1991;64(3):483-484.
2. Engberg N, Kahn M, Petersen DR, Hansson M, Serup P. Retinoic acid synthesis promotes development of neural progenitors from mouse embryonic stem cells by suppressing endogenous, Wnt-dependent nodal signaling. Stem Cells 2010;28(9):1498-1509. DOI: 10.1002/stem.479
3. Rhinn M, Dollé P. Retinoic acid signalling during development. Development 2012;139(5):843-858. DOI: 0.1242/dev.065938.
4. Marlézat F, Holland LZ, Laudet V, Schubert M. Retinoic acid signaling and the evolution of chordates. Int J Biol Sci. 2006;2(2):38-47.
5. Sharif J, Endo TA, Toyoda T, Koseki H. Divergence of CpG island promoters: a consequence or cause of evolution? Dev Growth Differ. 2010;52(6):545-554. DOI: 10.1111/j.1440-169X.2010.01193.x
6. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. PNAS. 2002;99(6):3740-3745.
7. Saxonov S, Berg P, Brutlag DL. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci USA. 2006;103(5):1412-1417.
8. Vavouri T, Lehner B. Human genes with CpG island promoters have a distinct transcription-associated chromatin organization. Genome Biol. 2012;13(11):R110. DOI: 10.1186/gb-2012-13-11-r110
9. Ponger L, Duret L, Mouchiroud D. Determinants of CpG island promoters: a consequence or cause of evolution? Trends Genet. 2008;24(10):481-484. DOI: 10.1016/j.tig.2008.08.004. Epub 2008 Sep 9
10. Zhu J, He F, Hu S, Yu J. On the nature of human housekeeping genes. Proc Natl Acad Sci USA. 2006;103(5):1412-1417.
11. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008;3(6):1101-1108.
12. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93(18):9821-9826.
13. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 2007;447(7143):425-432.
14. Horrocks GM, Lauder L, Stewart R, Przyborski S. Formation of neurospheres from human embryonal carcinoma stem cells. Biochem Biophys Res Commun. 2003;304(2):411-416.
15. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008;3(6):1101-1108.
suppressor gene by interferons is mediated through an ISRE and a GAS element. *Oncogene* 1995;11(12):2565-2573.

21. Khalfin-Rabinovich Y, Weinstein A, Levi B-Z. PML is a key component for the differentiation of myeloid progenitor cells to macrophages. *Int Immunol.* 2011;23(4):287-296. DOI: 10.1093/intimm/dxr004. Epub 2011 Mar 22

22. Korb E, Finkbeiner S. PML in the brain: from development to degeneration. *Front Oncol.* 2013;3. DOI: 10.3389/fonc.2013.00242

23. Gudas LJ, Wagner JA. Retinoids regulate stem cell differentiation. *J Cell Physio.* 2011;226(2):322-330. DOI: 10.1002/jcp.22417

24. Draper JS, Pigott C, Thomson JA, Andrews PW. Surface antigens of human embryonic stem cells: changes upon differentiation in culture. *J Anat.* 2002;200(3):249-258.

25. Bhattacharya B, Cai J, Luo Y, Miura T, Mejido J, Brimble SN, et al. Comparison of the gene expression profile of undifferentiated human embryonic stem cells and differentiating embryoid bodies. *BMC Dev Biol.* 2005;5(1):22.

26. Schulz TC, Palmirini GM, Noggle SA, Weiler DA, Mitalipova MM, Condie BG. Directed neuronal differentiation of human embryonic stem cells. *BMC Neurosci.* 2003;4(1):27.

27. Baharvand H, Mehrjardi N, Hatami M, Kiani S, Rao M, Haghhighi M. Neural differentiation from human embryonic stem cell lines in a defined adherent culture condition. *Int J Dev Biol.* 2007;51(5):371-378.

28. Bain G, Kitchens D, Yao M, Huettner JE, Gottlieb DI. Embryonic stem cells express neuronal properties in vitro. *Dev Biol.* 1995;168(2):342-357.

29. Yu E, Choi EK, Kim CJ. Expression of promyelocytic leukemia protein increases during the differentiation of human neuroblastoma cells. *Virchows Arch.* 2003;442(3):278-283.

30. Pleasure S, Lee VY. Ntera 2 cells: a human cell line which displays characteristics expected of a human committed neuronal progenitor cell. *J Neuro Res.* 1993;35(6):585-602.

31. Regad T, Bellodi C, Nicotera P, Salomoni P. The tumor suppressor Pml regulates cell fate in the developing neocortex. *Nat Neurosci.* 2009;12(2):132-140. DOI: 10.1038/nn.2251. Epub 2009 Jan 11

32. Guan D, Kao HY. The function, regulation and therapeutic implications of the tumor suppressor protein, PML. *Cell Biosci.* 2015;5(1):1. DOI: 10.1186/s13578-015-0051-9. eCollection 2015

33. Condemine W, Takahashi Y, Zhu J, Puvion-Dutilleul F, Guegan S, Janin A. Characterization of endogenous human promyelocytic leukemia isoforms. *Cancer Res.* 2006;66(12):6192-6198.

34. Kamitani T, Kito K, Nguyen HP, Wada H, Fukuda-Kamitani T, Yeh ET. Identification of three major sentrinization sites in PML. *J Biol Chem.* 1998;273(41):26675-26682.

35. Zhong S, Müller S, Ronchetti S, Freemont PS, Dejean A, Pandolfi PP. Role of SUMO-1–modified PML in nuclear body formation. *Blood* 2000;95(9):2748-2752.

36. Hsiao W-L, Everett RD. Human neuron-committed teratocarcinoma NT2 cell line has abnormal ND10 structures and is poorly infected by herpes simplex virus type 1. *J Virol.* 2001;75(8):3819-383.

37. Korb E, Wilkinson CL, Delgado RN, Lovero KL, Finkbeiner S. Arc in the nucleus regulates PML-dependent GluA1 transcription and homeostatic plasticity. *Nat Neurosci.* 2013;16(7):874-883. DOI: 10.1038/nn.3429. Epub 2013 Jun 9.

38. Cheng X, Kao HY. Post-translational modifications of PML: consequences and implications. *Front Oncol.* 2012;2:210. DOI: 10.3389/fonc.2012.00210. eCollection 2012